Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update
Inflammatory Bowel Diseases · 01.03.2026 · 32 (3) · 542-561
DOI: 10.1093/ibd/izaf228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.10.2025. Verfasst von Dimitrios Tsilimpotis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical School, University of Patras, 26504 Patras, Greece. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Skin Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, are immune-mediated disorders characterized by chronic gastrointestinal inflammation and a broad spectrum of extraintestinal manifestations. Among these, dermatological manifestations significantly impact patients’ quality of life (QoL), presenting as conditions linked to IBD itself or IBD-related medical therapy. This comprehensive review underscores the relationship between IBD and cutaneous manifestations, with particular emphasis on erythema nodosum, pyoderma gangrenosum, Sweet syndrome, and hidradenitis suppurativa, alongside autoimmune conditions like psoriasis and vitiligo. The influence of biologic therapies, including both paradoxical skin reactions mimicking extraintestinal manifestations and nonspecific rashes, is also discussed, with a focus on the pathophysiological mechanisms and therapeutic approaches. Emerging evidence highlights the bidirectional interplay of gut-skin axis, with shared genetic, microbial, and immune pathways. Special considerations, such as pregnancy-related dermatoses, are included to provide a holistic view of this complex relationship. Improved comprehension of these manifestations not only emphasizes the necessity for interdisciplinary care, but also informs tailored therapies to address systemic inflammation while minimizing dermatological complications. This update offers practical insights and emerging evidence to guide clinicians in optimizing patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Medical School, University of Patras, 26504 Patras, Greece.
- Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
- Zentrum für Gastroenterologie und Hepatologie, 8002 Zurich, Switzerland.
- Department of Gastroenterology and Hepatology, University Hospital Lausanne, 1011 Lausanne, Switzerland.
- Department of Gastroenterology and Hepatology, GZO-Zurich Regional Health Center, 8620 Wetzikon, Switzerland.
- Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, 5001 Aarau, Switzerland.
ORCID-Profile: Dimitrios Tsilimpotis, Georgia Kyriakou, Luc Biedermann, Stephan Vavricka, Thomas Greuter, Michael Doulberis
Zitieren
APA
Tsilimpotis, D., Kyriakou, G., Biedermann, L., Vavricka, S., Greuter, T., Rogler, G., & Doulberis, M. (2026). Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update. Inflammatory Bowel Diseases, 32(3), 542-561. https://doi.org/10.1093/ibd/izaf228
Vancouver
Tsilimpotis D, Kyriakou G, Biedermann L, Vavricka S, Greuter T, Rogler G, et al. Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update. Inflammatory Bowel Diseases. 2026;32(3):542-561. doi:10.1093/ibd/izaf228
BibTeX
@article{Tsilimpotis2026,
author = {Tsilimpotis, Dimitrios and Kyriakou, Georgia and Biedermann, Luc and Vavricka, Stephan and Greuter, Thomas and Rogler, Gerhard and Doulberis, Michael},
title = {Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {3},
pages = {542--561},
doi = {10.1093/ibd/izaf228}
}
EUVIMED